The Medicines Company Announces New Patent Issuance For Angiomax(R)
Main Category: Cardiovascular / CardiologyAlso Included In: Regulatory Affairs / Drug Approvals
Article Date: 03 Sep 2009 - 2:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  | |
| Healthcare Prof: | |
The Medicines Company (NASDAQ: MDCO) announced that the United States Patent and Trademark Office (PTO) issued a new U.S. patent No. 7,582,727 ('727 patent). The '727 patent relates to a more consistent and improved Angiomax drug product. The new patent has been submitted to the U.S. Food and Drug Administration (FDA) for listing in the FDA's publication "Approved Drug Products with Therapeutic Equivalence Evaluations," which is commonly known as the Orange Book, for Angiomax.
Angiomax is already protected under U.S. patent No. 5,196,404 ('404 patent), which covers the composition of matter of bivalirudin. The '404 patent expires on March 23, 2010. Additionally, Angiomax has been awarded pediatric exclusivity, which expires on September 23, 2010.
Source
The Medicines Company
Visit our cardiovascular / cardiology section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/162779.php>
APA
http://www.medicalnewstoday.com/releases/162779.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
